Oslo, 7 June 2021: Reference is made to the stock exchange release by EXACT
Therapeutics AS ("EXACT-Tx" or the "Company") on 7 June 2021 regarding a share
capital increase in connection with the Company's restricted stock unit (RSU)
programme.
 
Masha Strømme, chair of EXACT-Tx, has through her majority owned company PAACS
Invest AS, subscribed for 6,489 shares at NOK 20.804 per share. Following this
transaction, Masha Strømme will hold 2,684,739 shares in EXACT-Tx through PAACS
Invest AS.
 
Sir William Castell, vice-chair of EXACT-Tx, has subscribed for 9,998 shares at
NOK 20.804 per share. Following this transaction, Sir William Castell will hold
342,498 shares in EXACT-Tx.
 
Hans Henrik Klouman, board member of EXACT-Tx, has subscribed for 2,900 shares
at NOK 20.804 per share. Following this transaction, Hans Henrik Klouman will
hold 402,650 shares in EXACT-Tx through Virkelyst AS.
 
Aitana Peire, board member of EXACT-Tx, has subscribed for 5,030 shares at NOK
20.804 per share. Following this transaction, Aitana Peire will hold 5030 shares
in EXACT-Tx.

About EXACT-Tx
EXACT-Tx is a clinical stage Norwegian biotech company developing a technology
platform for targeted therapeutic enhancement - Acoustic Cluster Therapy (ACT®).
ACT® sonoporation is a unique approach to ultrasound-mediated, targeted drug
enhancement - with the potential to significantly amplify the clinical utility
of a wide range of therapeutic agents across a multitude of indications
including within oncology (chemotherapy, immunotherapy), infectious diseases,
and neurological conditions. www.exact-tx.com